Abstract: The invention relates to the oral cosmetic use of a combination of active agents comprising at least taurine, a derivative thereof and/or an acceptable salt thereof and at least one grape extract, as cosmetic active agents for improving the quality of the nails. More particularly, the present invention relates to the oral cosmetic use of such a combination for improving the solidity of the nails and for reducing and/or preventing their splitting.

Abstract: In certain aspects, the present disclosure provides for novel, water-soluble polyene macrolides and salts or solvates thereof and methods of making the water-soluble polyene macrolides. Also provided are compositions and methods for inhibiting, preventing, and/or treating fungal and parasitic diseases in a subject.

Abstract: The invention concerns a method for producing exopolysaccharides by fermenting micro-organisms characterised in that it consists in carrying out the fermentation in a nutrient medium comprising at least a source of carbon available to the micro-organisms and at least a source of nitrogen, said source being derived from a fraction of carob seed.

Abstract: New glycopeptide antibiotic A82846, comprising A82846A, A82846B and A82846C, is produced by Nocardia orientalis strains NRRL 18098, NRRL 18099 and NRRL 18100. The A82846 antibiotics have activity against Gram-positive bacteria comparable to that of vancomycin.

Abstract: The present invention concerns new antiobiotic substances demoninated de-acyl antibiotics A40926, de-acyl antibiotic A 40926P and antibiotic A 40926 amino glucronyl aglycon, and the use of these substances in the treatment of infectious diseases involving microorganisms susceptible to it.

Abstract: The invention is directed toward the use of amphotericin B and derivatives thereof as inhibitors of serine-proteases and for applying these inhibitors for the production of medicinal products intended for the treatment of infection by the human immunodeficiency virus (HIV).

Abstract: A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.

Abstract: A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.

Abstract: This invention concerns a method of preventing a pulmonary infection by a fungus in a subject susceptible to infection by the fungus comprising administering to the subject an amount per dose in an aerosol spray of a polyene or a pharmaceutically acceptable derivative thereof, effective to prevent pulmonary infection by the fungus. This invention further discloses a method of treating pulmonary aspergillosis in a subject comprising administering to the subject an amount per dose in an aerosol spray of a polyene, e.g., amphotericin B or pimaricin, or a pharmaceutically acceptable derivative thereof effective to treat aspergillosis.

Abstract: The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A, antibiotic A 40926 factor B, antibiotic A 40926 factor B.sub.0, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class of antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Abstract: This invention relates to new compounds WF 2015 A and B which have immunosuppressing activity and antitumor activity, to a process for producing WF 2015 A and B by culturing a WF 2015 A and/or B-producing strain belonging to the genus Scolecobasidium in a nutrient medium, and to a pharmaceutical composition comprising the same.

Abstract: An antibiotic F-0769 having the following properties:(1) Outer appearance: White or light yellow powder,(2) Melting point: 245.degree.-250.degree. C.,(3) Specific rotation: [.alpha.].sub.D.sup.25 =-37.5.degree. (c=1, methanol),(4) Solubility in solvents: Soluble in methanol, ethanol, acetone, chloroform, ethyl acetate and benzene; and insoluble in water and hexane,(5) Elementary analysis (found %): C:57.53, H:7.36, O:21.17, N:12.97,(6) Ultraviolet absorption spectrum (as measured in methanol: As shown in FIG. 1, .lambda.max(E.sub.1 cm.sup.1%)=213 nm (466), 286 nm (200)(7) Infrared absorption spectrum (as measured by KBr method): As shown in FIG. 2,(8) Nuclear magnetic resonance spectra (as measured in heavy chloroform): .sup.1 H-NMR spectrum is as shown in FIG. 3, and .sup.13 C-NMR spectrum is as shown in FIG. 4,(9) Distinction among basicity, acidity and neutrality: Neutral substance,(10) Amino acid analysis: As a result of the hydrolysis with 6N hydrochloric acid at 110.degree. C.

Abstract: A unique four-solvent system comprising methanol, dimethylformamide, methylene chloride and water is employed to provide an improved process for the purification and crystallization of amphotericin B.

Abstract: Methods and compositions useful for treating acquired immune deficiency syndrome by once daily administration of substances characteristic of acquired immune deficiency syndrome-afflicted cell (such as human chorionic gonadotropin), and effective fragments and derivatives thereof, in a pharmaceutically effective amount less that the lowest amount necessary to provoke a humoral immune response, as exemplified by the existence of a negative wheal upon subcutaneous administration. Illustrative of such methods and compositions is the administration of a composition including human chorionic gonadotropin (HCG), a lysate of Staphylococcus aureus, influenza virus vaccine, and fractionated HIV virus, including peptide T.

Abstract: The present invention concerns new antibiotic substances denominated antibiotic A 40926 N-acylaminoglucuronyl aglycon complex AB, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor A, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.0, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.1, antibiotic A 40926 aglycon and the addition salts thereof, a process for their preparation starting from antibiotic A 40926 complex or a factor thereof, and their use in the treatment of infectious diseases involving microorganisms susceptible to them.

Abstract: A method for the preparation of feed premix compositions of the antibiotic maduramicin which have improved stability of the antibiotic at elevated temperatures and the stable feed premix compositions prepared thereby.

Abstract: Promoting the growth of animals with a novel compound, named annomycin, by cultivation of Streptomyces strain BS 572, DSM 3817.

Abstract: A physiologically-active novel substance "aldostatin" having an estimated molecular formula of C.sub.20 H.sub.20 N.sub.2 O.sub.8 is produced by culturing an aldostatin-producing microorganism of the Pseudeurotium, for example, the Pseudeurotium zonatum M4109 strain. Aldostatin inhibits the aldose reductase activity and as a consequence, avoids abnormal accumulation of sorbitol, galactitol, etc. It is therefore effective for the treatment of chronic complications such as cataract, retinopathy and neuropathy caused by diabetes renalis.

Abstract: It has been discovered that rubradirin can be used to treat rubradirin-sensitive, methicillin-resistant staphylococcal infections.

Abstract: A hitherto undescribed microorganism, Streptomyces virginiae NRRL 12525, which upon culturing produces the A41030 antibiotic complex comprising several factors. The A41030 antibiotics produced show antibacterial activity against the gram-positive genera Staphylococcus and Streptococcus which are resistant to penicillin. In addition, these antibiotic act to promote growth and improve feed efficiency in ruminant animals, poultry and swine, and other livestock, and to improve milk production in ruminant animals.

Abstract: Antitumor agents LL-D49194.alpha..sub.1, LL-D49194.beta..sub.1, LL-D49194.beta..sub.2, LL-D49194.beta..sub.3, LL-D49194.gamma., LL-D49194.delta., LL-D49194.epsilon., LL-D49194.xi., LL-D49194.eta., LL-D49194.omega., LL-D49194.omega..sub.2 and LL-D49194.omega..sub.3.

Abstract: An antibiotic, Spicamycin, having the physicochemical properties set forth below is produced by aerobically cultivating a Spicamycin-producing Streptomyces strain in a suitable culture medium, and recovering from the culture the antibiotic, Spicamycin.(1) Color and properties: Weakly acidic white powder(2) Melting point: 215.degree. to 220.degree. C. (decomposed)(3) Specific rotatory power: [.alpha.].sub.D.sup.25 =+15.degree. (C: 0.15, in methanol)(4) Elementary analysis (Found): C: 57.4%, H: 8.3%; N: 15.7%, O: 18.6%(5) Ultraviolet absorption spectrum (maximum):______________________________________ CH.sub.3 OH 264 nm (E.sub.1cm.sup.1% 257) 0.01N NaOH + CH.sub.3 OH 272 nm (E.sub.1cm.sup.1% 226) 0.01N HCl + CH.sub.3 OH 273 nm (E.sub.1cm.sup.1% 258) ______________________________________(6) Infrared absorption spectrum (as measured by the potassium bromide method): As shown in FIG. 2.(7) Solubility in Solvent: Soluble in basic water, dimethyl sulfoxide, methanol, ethanol, n-propanol, and n-butanol.

Abstract: The invention refers to an individual antibiotic substance selected from the group consisting of Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 in substantially pure form, and to the method of producing them by recovery from Teichomycin A.sub.2, a known antibiotic substance, by means of high-efficiency chromatographic methods. The single pure Teichomycin A.sub.2 factor 1, Teichomycin A.sub.2 factor 2, Teichomycin A.sub.2 factor 3, Teichomycin A.sub.2 factor 4 and Teichomycin A.sub.2 factor 5 are biologically distinguishable from Teichomycin A.sub.2 in that they have a higher degree of antibiotic activity against susceptible microorganisms.

Abstract: A new antibiotic, designated S/433, is disclosed which is produced in a microbiological fermentation under controlled conditions using a new strain of Streptomyces. This new antibiotic is active against gram-positive and gram-negative bacteria and is also active in inhibiting the growth of transplanted tumors.

Abstract: Antibiotics Y-16482 .alpha. and/or Y-16482 .beta., obtained by cultivating a strain belonging to the genus Pseudomonas and capable of producing Y-16482, process of producing either or both of them, and a pharmaceutical composition containing these compounds. Antibiotics Y-16482 .alpha. and/or Y-16482 .beta. show an antibacterial activity to gram-positive and gram-negative bacteria and indicate an antitumor activity to experimental tumors.

Abstract: Disclosed is a novel antibiotic SF-2107 series substance consisting essentially of Substance SF-2107 A-1, Substance SF-2107 B and/or Substance SF-2107 C, each having the phisico-chemical properties as described in the specification, which substance exhibits an antibacterial activity against both gram-positive and gram-negative bacteria and is useful for pharmaceuticals, bactericides, disinfectants, etc. Also disclosed is a process for preparing the substance.

Abstract: A microorganism of the genus Acetinoplanes produces a novel complex of polyene antibiotics herein designated collectively Antibiotic 67-121 (and sometimes referred to as the Antibiotic 67-121 complex). The individual components are designated Antibiotic 67-121A, Antibiotic 67-121B, Antibiotic 67-121C and Antibiotic 67-121D. The individual components have ultraviolet spectra characteristic of heptaenes. Further, they are orally active against a variety of strains of Candida albicans including many clinical isolates thereof.

Abstract: A novel peptide antibiotic complex designated herein as Bu-2470 is produced by fermentation of Bacillus circulans strain G493-B6 (ATCC 31,805). Complex Bu-2470 may be separated into four bioactive peptide antibiotics designated as Bu-2470A, B.sub.1, B.sub.2a, and B.sub.2b. The complex and individual bioactive factors possess significant antimicrobial activity.

Abstract: A novel antibiotic C-14482 A.sub.1 is produced by cultivating a microorganism belonging to the genus Nocardia and capable of producing Antibiotic C-14482 A.sub.1 in a culture medium, whereby Antibiotic C-14482 A.sub.1 is elaborated and accumulated in the culture medium, and recovering the same antibiotic.Antibiotic C-14482 A.sub.1 is useful as a germicide or disinfectant.

Abstract: A novel antibiotic BN-235 substance and a process for making it are described, wherein the hydrochloride thereof has the following properties:Elemental analysis values:carbon 55.44%hydrogen 6.41%nitrogen 9.02%chlorine 12.01%oxygen 17.12% (balance)Molecular weight: about 520 (by the vapor pressure method)Melting point: 230.degree. to 232.degree. C. (decomp.)Ultraviolet absorption spectrum: shown in FIG. 1Infrared absorption spectrum: shown in FIG. 2Color reactions:Positive: ninhydrin and LemieuxNegative: Sakaguchi and ferric chlorideColor and form: yellow powderSolubility: soluble in methanol, ethanol, acetone and water, and insoluble in ether, n-hexane and petroleum etherStability: stable at a pH of 2 to 6Rf values in thin-layer chromatography (silica gel):chloroform-methanol (4:1) 0.73n-butanol-acetic acid-water (2:1:1) 0.64Distinction among acidity, neutrality and basicity:basic.

Abstract: A new antibiotic, designated kristenin, is produced by the microorganism Bacillus subtilis. The antibiotic possesses activity against gram positive bacteria.

Abstract: A novel anthracycline antibiotic complex, fragilomycin complex, is produced by the cultivation of a fermentation broth containing Streptosporangium fragilis Shearer sp. nov. ATCC 31519 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The fragilomycin complex and its major bioactive component, fragilomycin A, exhibit antibiotic activity.

Abstract: Novel antibiotics C-14482 B.sub.1, B.sub.2 and B.sub.3 are produced by cultivating a microorganism belonging to the genus Nocardia and capable of producing Antibiotics C-14482 B.sub.1, B.sub.2 and/or B.sub.3 in a culture medium, whereby Antibiotics C-14482 B.sub.1, B.sub.2 and/or B.sub.3 are elaborated and accumulated in the cultured broth and are recovered.Antibiotics C-14482 B.sub.1, B.sub.2 and B.sub.3 are useful as a germicide or disinfectant, respectively.

Abstract: A method of treating inflammation comprising topical administration to mammals suffering from an inflammatory condition not associated with amicrobial component, employing selected antibiotics as the anti-inflammatory agent.

Abstract: Antibiotic X-14868A having the following chemical structure ##STR1## and the pharmaceutically acceptable salts thereof is presented. Also presented is a fermentative method of producing the above antibiotic.Antibiotic X-14868A exhibits anticoccidiostatic activity.

Abstract: In-vivo hydrolysable esters of certain .alpha.-amino penicillins and cephalosporins have been rendered relatively tasteless by formulating into reconstitutable powders with a disodium or dipotassium salt of a di-carboxylic amino acid or tri- or di-sodium or -potassium phosphate, tartrate or citrate.

Abstract: A microorganism of the genus Actinoplanes produces a novel complex of polyene antibiotics herein designated collectively Antibiotic 67-121 (and sometimes referred to as the Antibiotic 67-121 complex). The individual components are designated Antibiotic 67-121A, Antibiotic 67-121B, Antibiotic 67-121C and Antibiotic 67-121D. The individual components have ultraviolet spectra characteristic of heptaenes. Further, they are orally active against a variety of strains of Candida albicans including many clinical isolates thereof.

Abstract: Antibiotics aculeacin-A.alpha., -A.gamma., -D.alpha. and -D.gamma. are active against yeasts and fungi. They are produced by culturing the microorganism Aspergillus aculeatus NRRL 11270 in a nutrient medium containing assimilable carbon and nitrogen sources.

Abstract: Substance SF-1739 derivatives, Substance SF-1739 HP, Substance SF-1739 HP-C, Substance SF-1739 HP-F, Substance SF-1739 HP-3 and Substance SF-1739 HP-5, the physico-chemical properties of which derivatives are described in the specification; processes for preparing such SF-1739 derivatives; and antimicrobial compositions containing at least one of the said Substance SF-1739 derivatives.

Abstract: Antibiotics of the formula ##STR1## wherein R is .alpha.-3,4-di-O-methylrhamnosyl, are produced by the cultivation of Streptomyces capreolus NRRL 11429 under submerged aerobic fermentation conditions. A crude antibiotic mixture is obtained from the fermentation medium by extraction. The compounds of Formula II, III, and IV are separated from coproduced Antibiotic A201A (See U.S. Pat. No. 3,843,784) and from each other by repetitive chromatography on silica gel.

Abstract: Acetone or methanol saturated with sodium iodide or sodium thiocyanate are useful solubilizing media for amphotericin B.

Abstract: This invention provides S 31794/F-1 which is a useful anti-mycotic for combatting Candida albicans infections.

Abstract: A species of Actinoplanes, designated Actinoplanes deccanensis Parenti, Pagani and Beretta subsp. salmoneus Huang subsp. nov., ATCC 31355, when subjected to submerged aerobic fermentation, produces a new antibiotic complex. Methods for the recovery and purification of the antibiotic complex and some of the individual antibiotic components are described.

Abstract: A species of Actinoplanes, designated Actinoplanes auranticolor ATCC 31011, when subjected to submerged aerobic fermentation under controlled conditions, produces a mixture of antibiotics which includes a number of macrocyclic lactones and depsipeptides. The individual compounds exhibit significant antibiotic activity. The crude antibiotic mixture or combinations of a pure macrocyclic lactone and a pure depsipeptide demonstrate marked synergistic antibiotic activity. These antibiotics act as growth promotants in chicks and swine and are effective in the treatment of swine dysentery.This mixture of antibiotics is also produced by a species of Actinoplanes designated Actinoplanes azureus ATCC 31157. In addition, this culture produces a mixture of heptaene antibiotics with antifungal properties.

Abstract: A method for the topical treatment of acne with antibiotic A-201A and A-201A compositions for acne are disclosed.

Abstract: The disclosure relates to a method for use in the practice of animal husbandry which comprises the oral administration to meat producing animals a compound of the aureolic acid group. Solid and liquid compositions for use in the method are also disclosed, together with a novel process for the manufacture of mixed mithramycins, and an improved process for their purification.

Abstract: Disclosed are degradation products of the antibiotics rubradirin and rubradirin B and processes for their preparation. Some of these products have antibacterial activity, and, thus, can be used in various environments to inhibit susceptible bacteria. Also, some of these products can be used as intermediates to make useful antibacterials.

Abstract: Antifungal compositions useful for the treatment of ringworm and other fungal infections comprising an antifungally effective amount of natamycin and a non-toxic, pharmaceutically acceptable organic acid compound and a suitable liquid carrier which compositions may be sprayed onto the animal, applied by a sponge or by other topical administration and concentrate comprising natamycin and the non-toxic, pharmaceutically acceptable organic acid compound in dry form.

Abstract: Orally administered compositions for altering lipid metabolism are described herein, these compositions containing an effective dose of antibiotic SCH-16656. Also the method of altering lipid metabolism including reducing and controlling the blood cholesterol level is described herein.

Abstract: Orally administered compositions for treating prostatic hypertrophy are described herein. These compositions contain an effective dose of a pharmaceutical formulation containing antibiotic SCH-16656. Also, the method of treating prostatic hypertrophy with such compositions is described herein.